Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-08-24
2010-11-16
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S227000
Reexamination Certificate
active
07833998
ABSTRACT:
The treatment of neurological disorders using cephalosporin sulfoxide-containing and/or cephalosporin sulfone-containing compositions and pharmaceutical compositions including oral dosage forms that include cephalosporin sulfoxide and/or sulfone-containing compositions are described.
REFERENCES:
patent: 3275626 (1966-09-01), Morin et al.
patent: 4138555 (1979-02-01), Cook et al.
patent: 4237128 (1980-12-01), Cimarusti et al.
patent: 4275062 (1981-06-01), Breuer et al.
patent: 4349672 (1982-09-01), Montavon et al.
patent: 4399131 (1983-08-01), Durckheimer et al.
patent: 4547371 (1985-10-01), Doherty et al.
patent: 4992431 (1991-02-01), Heymes et al.
patent: 5077286 (1991-12-01), Bissolino et al.
patent: 5147871 (1992-09-01), Albrecht et al.
patent: 5258377 (1993-11-01), Maiti et al.
patent: 5264429 (1993-11-01), Maiti et al.
patent: 5264430 (1993-11-01), Maiti et al.
patent: 5364848 (1994-11-01), Doherty et al.
patent: 5439904 (1995-08-01), Maiti et al.
patent: 5442058 (1995-08-01), Nieuwenhuis
patent: 5446037 (1995-08-01), Maiti et al.
patent: 5580865 (1996-12-01), Alpegiani et al.
patent: 5760027 (1998-06-01), Buynak et al.
patent: 6489319 (2002-12-01), Koppel et al.
patent: 6495539 (2002-12-01), Hultgren et al.
patent: 6627625 (2003-09-01), Koppel
patent: 6916801 (2005-07-01), Buynak et al.
patent: 7112582 (2006-09-01), Venkatesan et al.
patent: 7384928 (2008-06-01), Nishitani et al.
patent: 2002/0142950 (2002-10-01), Hayward et al.
patent: 2003/0003526 (2003-01-01), Tsien et al.
patent: 2007/0249523 (2007-10-01), Koppel et al.
patent: 2008/0009634 (2008-01-01), Winkley et al.
patent: 1031768 (1978-05-01), None
patent: 635104 (1983-03-01), None
patent: 635105 (1983-03-01), None
Wendel, Anesthesiology. 96(4):913-920, Apr. 2002.
Richter, Wolfgang F.; Chong, Yong H.; Stella, Valentino J.; “On the Mechanism of Isomerization of Cephalosporin Esters”, Journal of Pharmaceutical Sciences, vol. 79, No. 2, Feb. 1990, pp. 185-186.
Vorona, Maxim.; Veinberg, G.; Shestakova, I.; Kanepe, I.; Lukevics, E.; “Anticancer Activity in Vitro of Some Amides and Esters of 7α Chlorodeacetoxycephalosporanate Sulfone”, RTU zinatniskie raksti, Materialzinatne un lietiska kimija 5, Sejuns 2002.g. pp. 190-194.
Adams, D.B. “Brain Mechanisms for Offense, Defense and Submission,”The Behavioral Brain Sciences2:201-241 (1979).
Albert, D.J. and Walsh, M.L., “Neural systems and the inhibitory modulation of agonistic behavior: a comparison of mammalian species,”Neurosci Biobehav Rev8(1):5-24 (1984).
Baumann MH, et al., “Effects of Phentermine and Fenfluramine on Extracellular Dopamine and Serotonin in Rat Nucleus Accumbens: Therapeutic Implications,” Synapse 36(2):102-113 (2000).
Blanchard, D.C. (1984)Applicability of animal models to human aggressionIn: Biological Perspectives on Aggression, Alan R. Liss, Inc., pp. 49-74.
Blanchard, R.J., Blanchard, D.C., “Aggressive behavior in the rat,”Physiology and Behavior1:197-224 (1977).
Cartmell, J et al., “Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum,” Brain Research 887(2):378-384 (2000).
Cartmell, J. et al.. “The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat,” J Neurochemistry 75(3):1147-1154 (2000).
Charney, DS, and Bremner, JD (1999) The neurobiology of anxiety disorder. In: Neurobiology of Mental Illness (Charney, DS, et al eds.), Oxford University Press, New York, pp. 494-517.
Coccaro, EF et al., “Cerebrospinal Fluid Vasopressin Levels: Correlates With Aggression and Serotonin Function in Personality-Disordered Subjects,” Arch Gen Psychiatry 55(8):708-14 (1998).
Crusio, WE et al., “Radial-Maze Performance and Structural Variation of the Hippocampus in Mice: A Correlation With Mossy Fibre Distribution,” Brain Research 425(1):182-5 (1987).
Feighner JP, “Overview of Antidepressants Currently Used to Treat Anxiety Disorders,” J Clin Psychiatry 60:18-22 (1999).
Ferris, C.F., & Potegal, M., “Vasopressin receptor blockade in the anterior hypothalamus suppresses aggression in hamsters,”Physiology and Behavior44:235-239 (1988).
Ferris, C.F., et al., “Scent marking and the maintenance of dominant/subordinate status in male golden hamsters,” Physiology and Behavior 40:661-664 (1987).
Ferris, C.F., et al., “Vasopressin/Serotonin Interactions in the Anterior Hypothalamus Affect Aggressive Behavior in Golden Hamsters,” J Neuroscience 17:4331-4340 (1997).
Hertel P, et al., “Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain,” Psychopharmacology (Berl) 124(1-2):74-86 (1996).
Johnston, R.E. (1985) Communication, In: The Hamster Reproduction and Behavior. Ed Siegel, H.I. Plenum Press, New York, pp. 121-154.
King, JA et al., Seed Finding in Golden Hamsters: A Potential Animal Model for Screening Anxiolytic Drugs,Neuropsychobiology45:150-155 (2002).
McKinney, W.T. (1989)Basis of development of animal models in psychiatry: An overview.In: Animal Models of Depression, Eds. G.G. Koob, C.L. Ehlers, E.J. Kupfer Birkanser, Boston.
Olton, D.S., & Samuelson, R.J., “Remembrance of Places Passed—Spatial Memory in Rats,” J Exp Psychol Anim Behav Processes 2(2):97-116 (1976).
Pellow, S et al., “Validation of Open :Closed Arm Entries in an Elevated Plus-Maze As a Measure of Anxiety in the Rat,”Journal of Neuroscience Methods14(3):149-167 (1985).
Rothman, RB et al., “Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors,” J Subst Abuse Treat 11:273-275 (1994).
Weintraub, M, et al., “A Double-Blind Clinical Trial in Weight Control. Use of Fenfluramine and Phentermine Alone and in Combination,” Arch Intern Med 144(6):1143-8 (1984).
Batueva, I.V., Veselkin, N.P., Veskov, R., “Effect of Penicillin on the Synaptic Activity of Isolated Spinal Cord Motor Neurons in the Lamprey,” Neirofiziologiia, vol. 24, No. 2, 1992, English Abstract, 2 pages.
Bashir, Z.I., Holmes, O., “N-methyl-D-aspartate Receptors and the Enhancement of Somatosensory Evoked Potentials in Penicillin Epileptogenesis in Rats,” Physiological Society, Mar. 1987, 1 page.
Horn, E., Esseling, K., Wagner, R., “Time Course of Interictal EEG Patterns Induced by a Penicillin Injection Into the Olfactory Cortex,” Pharmacology Biochemistry & Behavior, vol. 40, 1991, pp. 351-357.
Home, A.L., Hadingham, K.L., Macaulay, A.J., Whiting, P., Kemp, J.A., “The Pharmacology of Recombinant GABAAReceptors Containing Bovine α1, β1, γ2LSub-Units Stably Transfected Into Mouse Fibroblast L-Cells,” Br. J. Pharmacol. vol. 107, 1992, pp. 732-737.
Kalueff, A.V., Samonina, G.E., Ashmarin, I.P., “Penicillins and Their Derivatives: Antiulcer/Antistress Properties?,” Neuropsychoharmacology, vol. 10, No. 36, Part 2, 1994, 1 page.
Orwar, O., Li, X., Andine, P., Bergstrom, C.M., Hagberg, H., Folestad, S., Sandberg, M., “Increased Intra- and Extracellular Concentrations of γ-Glutamylglutamate and Related Dipeptides in the Ischemic Rat Striatum: Involvement of γ-Glutamyl Transpeptidase,” Journal of Neurochemistry, vol. 63, 1994, pp. 1371-1376.
Serval, V., Barbeito, L., Pittaluga, A., Cheramy, A., Lavielle, S., Glowinski, J., “Competitive Inhibition of N-Acetylated-α-Linked Acidic Dipeptidase Activity by N-Acetyl-L-Aspartyl-β-Linked L-Glutamate,” Journal of Neurochemistry, vol. 55, 1990, pp. 39-46.
Varga, V., Janaky, R., Saransaari, P., Oja, S.S., “Endogenous γ-L-Glutamyl and
Chaney Michael O.
Koppel Gary A.
Berch Mark L
Gollin Michael A.
Haddaway Keith G.
Revaax Pharmaceuticals, LLC
Venable LLP
LandOfFree
Oral neurotherapeutic cephalosporin sulfoxide and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral neurotherapeutic cephalosporin sulfoxide and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral neurotherapeutic cephalosporin sulfoxide and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176842